instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: South Korea’s agriculture ministry said North Korea reported to the World Organization for Animal Health that 77 of the 99 pigs at a farm in Jagang province died of the disease and another 22 pigs were culled. The outbreak in North Korea comes after the disease in past months ravaged farms in China, where more than a million pigs have been reportedly culled, and also spread to Vietnam, Cambodia and Mongolia. The disease is harmless to humans but for pigs is fatal and highly contagious, and there is no known cure or vaccine. North Korea’s official Rodong Sinmun newspaper on Friday published three different articles detailing the spread of the African swine fever across Asia, but none of them mentioned that the disease has reached the North. Oh Soon-min, director of quarantine policies at South Korea’s agriculture ministry, said quarantine measures and blood tests will be stepped up in some 350 pig farms near the inter-Korean border. Fences and traps will also be installed near the farms to prevent the pigs from contacting wild boars that roam in and out of North Korea. “While North Korea’s Jagang province, where the outbreak of the African swine fever was confirmed, is near the border between North Korea and China, we do believe this is a serious situation as there is a possibility that the disease can spread toward the South,” Oh said. He said the South Korean government believes the North raises about 2.6 million pigs in 14 government-run or cooperative farms. The South hopes to discuss the issue with North Korea at an inter-Korean liaison office and find ways to help the North fight the spread, said Eugene Lee, a spokeswoman from Seoul’s Unification Ministry, which deals with inter-Korean affairs. The outbreak comes as the North has significantly slowed its engagement with South Korea following the collapse of a February summit between North Korean leader Kim Jong Un and U.S. President Donald Trump. Lee said the South had told the North “several times” that it could help in case of African swine fever outbreak, but did not confirm how North Korean officials responded. Claim: Seoul: North Korea confirms African swine fever outbreak.
answer:
South Korea said Friday that it is scrambling to prevent the spread of the highly contagious African swine fever on its pig industry after North Korea confirmed an outbreak at a farm near its border with China.


question:
Paragraph: The story does not mention the cost of mammography (or of follow up tests and treatments) to the individual, or, collectively, to society. And these costs are substantial. Based on the results of this study, 2,500 women would have to be screened every other year for a decade in order to prevent one death from breast cancer. As the story points out, during that same time 1,000 of those women would have at least one false alarm and 500 would undergo an unnecessary biopsy, thus adding to the price tag. On balance, this story does a fair job of describing the benefits of screening mammography as seen in this study. It reports the apparent 10 percent reduction in breast cancer deaths, while also pointing out that because relatively few women in the 50-69 age group die of breast cancer, that reduction can also be described as cutting the 10-year risk of death from 4.4 per 1,000 women to 4 per 1,000. The second statistic helps counteract popular assumptions about how many middle-aged women die from breast cancer. However, the framing of a story – and who gets the last word – sometimes overwhelms evidence-based explanations earlier in the story. That almost happened with this story, which gives the final word to an advocate of annual breast cancer screening for all women beginning by age 40, which is just the sort of blanket recommendation this latest study calls into question. The story includes a comment that because mammograms detect lumps that would not have become life-threatening, five to 15 women may be treated for every one whose life is saved by treatment. The story oversimplifies the methods used by researchers, saying they compared “women who were similar in most ways, except that one group received mammograms and the other didn’t,” without explaining that this was not a randomized trial where some women were assigned to screening and others weren’t, but rather an observational study that looked at data on women during a 9-year period when Norway phased in mammography region by region. The story does alert readers to some of the limitations of the study: one, that a longer follow-up period might have shown more benefit to screening and, two, that the researchers had no information on whether any of the women received mammograms outside of the national screening program. It’s a tossup for us to grade and, as we do in most such cases, we’ll give the story the benefit of the doubt. Claim: Mammogram benefits more modest than doctors thought
answer:
However, it does not explain to readers what is new or different about this study compared to earlier reports. Also, the final word in the story goes to an expert who touts benefits of mammography screening that clash with what was seen in this study. By comparing this story with, for example, the Philadelphia Inquirer and WebMD stories, you see how some of the gaps we’ve identified were addressed by competitors, giving readers a more complete and helpful story.


question:
Paragraph: "The story includes the cost of this test $1,625 and mentions that insurance companies currently don’t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman’s lifetime risk of developing cancer. There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test. Most experts advise against women taking this test, and the American Cancer Society does not promote the test. The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening. Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy). The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. Additionally, peer-reviewed studies need to be done to determine the best course of prevention if a woman chooses to take the test and discovers she is at higher risk of developing breast cancer. Because the story raised appropriate questions about the quality of the evidence, we give this a satisfactory score. The story lists the annual incidence of new breast cancers and mortality rate. The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman’s decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen. Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test–unlike Decode’s chief executive, who is also interviewed, mainly promoting his company’s product. Researchers help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts. The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer  mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review. The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women’s risk. The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test." Claim: Firm says test judges risk for common breast cancers
answer:

"The focus of the story is a newly available genetic test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there is concern about the validity of such tests that have not been subjected to external review. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. The story mentions current prevention guidelines for women who are considered higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However,the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. It is not clear how the new genetic test improves on this current practice, as there was no evidence presented. Researchers and clinicians interviewed help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts."